BTAIQ
What one share of BioXcel Therapeutics holds
Pharmaceutical Preparations
BioXcel Therapeutics, Inc. (Nasdaq: BTAI, “the Company”) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology.
BioXcel Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.03 |
|---|---|
| Profit | −$3.15 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.26 |
| Cash and investments | $0.41 |
| Debt | $3.34 |
| Book value | −$3.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.47 | — | −$0.23 | — | −$0.10 |
| 2018 | — | −$1.32 | $0.02 | −$0.95 | — | $2.48 |
| 2019 | — | −$2.02 | $0.05 | −$1.72 | — | $1.49 |
| 2020 | — | −$3.79 | $0.01 | −$3.07 | — | $8.47 |
| 2021 | — | −$4.05 | $0.02 | −$3.13 | — | $7.92 |
| 2022 | $0.01 | −$5.92 | $0.01 | −$4.84 | — | $2.73 |
| 2023 | $0.76 | −$98.33 | $0.01 | −$85.13 | — | −$30.20 |
| 2024 | $0.89 | −$23.51 | $0.00 | −$28.41 | — | −$30.01 |
| 2025 | $0.05 | −$5.73 | $0.00 | −$4.72 | — | −$4.28 |